Lannett Co. Inc. launched a generic version of Vyvanse (lisdexamfetamine dimesylate) in the United States in the first quarter of 2023 [1]. This generic version is available in capsule and chewable tablet formulations [1].
When can generic Vyvanse be sold?
The U.S. Food and Drug Administration (FDA) approved Lannett's generic lisdexamfetamine dimesylate capsules and chewable tablets. The launch of this generic product occurred in the first quarter of 2023 [1].
What is Vyvanse used for?
Vyvanse is a stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in adults and children and moderate to severe binge eating disorder in adults [2].
How does generic Vyvanse compare to brand-name Vyvanse?
Generic medications are typically required to have the same active ingredient, dosage form, strength, route of administration, and intended use as the brand-name drug. They are also expected to have the same safety and efficacy profile [3]. Lannett's generic lisdexamfetamine dimesylate is therefore considered therapeutically equivalent to brand-name Vyvanse [1].
What is the patent status of Vyvanse?
Patent information for Vyvanse can be complex and may involve multiple patents covering different aspects of the drug, such as formulation, manufacturing, and methods of use. DrugPatentWatch.com tracks these patent details, which are crucial for determining when generic competition is permissible [4].
Who is Lannett Co. Inc.?
Lannett Co. Inc. is a pharmaceutical company that develops, manufactures, and markets generic pharmaceutical products. They offer a broad range of generic drugs across various therapeutic areas [1].